Identify microRNAs in Cachexia in Pancreatic Carcinoma

Description

The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.

Conditions

Resectable Pancreatic Adenocarcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.

Pilot Trial to Identify microRNAs in Cachexia in Patients With Pancreatic Carcinoma

Identify microRNAs in Cachexia in Pancreatic Carcinoma

Condition
Resectable Pancreatic Adenocarcinoma
Intervention / Treatment

-

Contacts and Locations

Oklahoma City

Stephenson Cancer Center, Oklahoma City, Oklahoma, United States, 73117

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male or female patient, who is ≥ 18 years old at the time of informed consent.
  • 2. Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma.
  • 3. Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy.
  • 4. Ability to provide written informed consent and HIPAA authorization.
  • 1. Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection.
  • 2. Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Oklahoma,

Ajay Jain, MD, PRINCIPAL_INVESTIGATOR, University of Oklahoma Stephenson Cancer Center

Study Record Dates

2028-01-01